Oxford BioDynamics PLC Board Transition (6732A)

TIDMOBD

RNS Number : 6732A

Oxford BioDynamics PLC

31 May 2019

31 May 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Transition

Alison Kibble steps down from OBD Board after 11 years' service

Further to the announcement of 11 January 2019, Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that Alison Kibble has today stepped down from the Board as Non-Executive Director.

Alison first joined OBD's Board in December 2007 as a representative of the University of Oxford and since the Company's IPO has served as Chair of the Audit Committee and as a member of the Nomination and Remuneration Committees.

Following Alison's stepping down, membership of the sub-committees of the Board is as follows:

 
 Sub-committee            Chair            Other members 
 Audit committee          David Holbrook   Peter Pack 
                         ---------------  ------------------------ 
 Nomination committee     Stephen Diggle   David Holbrook 
                                            Christian Hoyer Millar 
                         ---------------  ------------------------ 
 Remuneration committee   Peter Pack       David Holbrook 
                         ---------------  ------------------------ 
 

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

"On behalf of the Board I would like to thank Alison for her many years of service to OBD. It has been a pleasure to work with her since the Company was spun out of the University of Oxford in 2007. Alison has offered the Executive Directors consistent support and challenge throughout her tenure as a Non-Executive Director, benefiting the Company and its shareholders. We will miss her, and wish her every future success."

Alison Kibble added:

"It has been a real privilege to be part of the team that has seen OBD grow from a small company into a successful listed entity with world-class technology and partnerships with major pharma and institutions. I wish the Board and all the employees well as they take the Company forward into the next exciting phase."

-ENDS-

For further details please contact:

 
 Oxford BioDynamics Plc 
  Christian Hoyer Millar, 
  CEO 
  Paul Stockdale, CFO                 [phone] 
 
   Shore Capital 
   Nominated Advisor and Broker 
   Stephane Auton 
   Edward Mansfield                  [phone] 
 
   FTI Consulting 
   Financial Public Relations 
   Adviser 
   Brett Pollard 
   Natalie Garland-Collins           [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOALLFSRERIIVIA

(END) Dow Jones Newswires

May 31, 2019 02:00 ET (06:00 GMT)